Logo

BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors

Share this
BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors

BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors

Shots:

  • ImmixBio to assess the safety- tolerability- and efficacy of IMX-110 in combination with tislelizumab in a P-I/IIa trial in patients with advanced solid tumors
  • The novel approach of combining ImmixBio’s tissue specific therapeutics (TSTx) with immunotherapies could expand the population of cancer patients experiencing extended remissions
  • The pre-clinical studies showed IMX-110 turns "cold" tumors "hot-" and IMX-110 + murine anti-PD-1 demonstrated extended survival in a genetic mouse model of pancreatic cancer vs multi-drug combinations in the literature showed substantial rationale to combine IMX-110 and tislelizumab

| Ref: PR Newswire | Image: BeiGene

Click here to­ read the full press release 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions